With a couple of wins this month, Sandoz Inc. can boast that it beat Amgen Inc. in district court, the Federal Circuit, and the Supreme Court in a single year in a long-running battle over its filgrastim and pegfilgrastim biosimilar products.
The U.S. District Court for the Northern District of California ruled Dec. 19 Sandoz’s method for making and purifying filgrastim and pegfilgrastim, which are white blood cell boosters, does not infringe an Amgen patent. Sandoz’s filgrastim biosimilar, Zarxio, is the first FDA-approved biosimilar, with Amgen’s Neupogen as the reference product. Amgen’s longer-lasting Neulasta is the reference product for Sandoz’s yet-to-be approved pegfilgrastim biosimilar.
The U.S. Court of Appeals for the Federal Circuit ruled Dec. 14 the Biologics Price Competition and Innovation Act preempts state law and prevents biologic reference product holders like Amgen from relying on state remedies to force biosimilar applicants to participate in the BPCIA’s information disclosure “patent dance.” Amgen had argued Sandoz violated California unfair-competition and conversion laws when it refused to dance.
And the Supreme Court ruled against Amgen as well June 12, holding that a biosimilar applicant does not need to wait until the FDA licenses its product before providing the BPCIA-required 180 days’ notice to reference product holders before marketing it. The court also held the BPCIA does not provide a federal remedy, such as obtaining an injunction, to force a biosimilar applicant to dance. (The court left it to the Federal Circuit to address whether state-law remedies were available, which led to Sandoz’s win there this month.)
While the district court win smooths the path for a specific Sandoz biosimilar effort, the appellate and high court triumphs in 2017 benefit biosimilar makers as a whole, providing them more options on how and when to address patent issues while bringing their products to market.
Read my story on the district court decision here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)